2 Stocks to Protect Yourself From a 2026 Market Crash

Last week, I noted how December is typically a great time to buy stocks.   Holiday shopping and corporate “use it or lose it” budgets mean that retailers and enterprise software firms alike see their highest sales during this period.

InvestorPlace • Nov 16, 2025

Why Bloomin' Brands Stock Continues to Nosedive

Losses are adding up while margins shrink for the restaurant company. Competitors are gaining ground.

The Motley Fool • Nov 13, 2025

Bloomin' Brands: Still Cheap For A Reason

Bloomin' Brands (BLMN) remains an underperformer, with ongoing margin pressure, weak traffic, and a recent dividend suspension highlighting operational challenges. BLMN's turnaround plan includes operational improvements, significant capex, and potential asset sales, but meaningful margin recovery is at least a year or two away. Despite positive same-store sales, gains are driven by price increases, not traffic, and the balance sheet remains burdened by high debt and weak cash flow.

Seeking Alpha • Nov 10, 2025

Outback Steakhouse abruptly shutters 21 restaurants in sweeping overhaul

Tampa-based operator Bloomin' Brands said in an earnings filing Thursday that the closures mark the start of a "comprehensive turnaround strategy."

New York Post • Nov 6, 2025

Bloomin' Brands Implements Turnaround Strategy Amid Quarterly Loss

Bloomin' Brands will implement a turnaround strategy, with a key focus on its Outback Steakhouse banner, as it aims to drive long-term sustainable and profitable growth.

WSJ • Nov 6, 2025

Bloomin' Brands, Inc. (BLMN) Q3 2025 Earnings Call Transcript

Bloomin' Brands, Inc. ( BLMN ) Q3 2025 Earnings Call November 6, 2025 9:00 AM EST Company Participants Tara Kurian - Senior VP of IR, FP&A, and International Michael Spanos - CEO & Director Eric Christel - Executive VP & CFO Conference Call Participants Anisha Datt - Barclays Bank PLC, Research Division Jeffrey Farmer - Gordon Haskett Research Advisors Brian Mullan - Piper Sandler & Co., Research Division Jon Tower - Citigroup Inc., Research Division Brian Vaccaro - Raymond James & Associates, Inc., Research Division Sara Senatore - BofA Securities, Research Division Edward Farley - Goldman Sachs Group, Inc., Research Division Presentation Operator Greetings, and welcome to the Bloomin' Brands Fiscal Third Quarter 2025 Earnings Conference Call. [Operator Instructions] It is now my pleasure to introduce your host, Tara Kurian, Senior Vice President, IR, FP&A and International.

Seeking Alpha • Nov 6, 2025

Bloomin' Brands Announces Turnaround Strategy, Releases 2025 Q3 Financial Results

TAMPA, Fla.--(BUSINESS WIRE)--Bloomin' Brands, Inc. (Nasdaq: BLMN) today reported results for the third quarter 2025 (“Q3 2025”) compared to the third quarter 2024 (“Q3 2024”). CEO Comments “We have great momentum in our business as demonstrated by our third quarter results,” said Mike Spanos, CEO. “All four brands drove positive comparable store sales growth for the first time since Q1 2023. Our teams continue to focus on consistency of execution in food quality and the guest experience, the f.

Business Wire • Nov 6, 2025

Bloomin' Brands (BLMN) Reports Q3 Loss, Beats Revenue Estimates

Bloomin' Brands (BLMN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.21 per share a year ago.

Zacks Investment Research • Nov 6, 2025

Bloomin' Brands (BLMN) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Bloomin' Brands (BLMN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Nov 6, 2025

Earnings Preview: Bloomin' Brands (BLMN) Q3 Earnings Expected to Decline

Bloomin' Brands (BLMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 30, 2025